Glomerulosclerosis Clinical Trials

A listing of Glomerulosclerosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 18 clinical trials
Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in subjects with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).

apolipoprotein l1
kidney biopsy
  • 83 views
  • 20 Jul, 2021
  • 45 locations
A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)

The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple intravenous infusion in adult subjects with FSGS.

tubulointerstitial fibrosis
focal segmental glomerulosclerosis
glomerular filtration rate
total protein
immunosuppressive agents
  • 226 views
  • 01 Aug, 2021
  • 104 locations
Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation

This study will evaluate the use of Acthar in patients to undergo renal transplantation and will measure the rate of FSGS recurrence.

acthar
kidney transplant
  • 33 views
  • 27 Jan, 2021
  • 1 location
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

segmental glomerulosclerosis (FSGS) in Japan and referred in the Guidelines for the Treatment of Nephrotic Syndrome endorsed by The Japanese Society of Nephrology. This study is conducted as a post

plasma cholesterol
kidney transplant
remission
nephrotic syndrome
low density lipoprotein
  • 36 views
  • 07 May, 2021
  • 8 locations
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

This is a phase III, multicenter, randomized, open label, clinical trial to test that hypothesis that plasmapheresis plus rituximab prior to kidney transplantation can prevent recurrent FSGS in children and adults.

hepatitis c
kidney transplant
absolute neutrophil count
obesity
nephrotic syndrome
  • 83 views
  • 25 Jan, 2021
  • 1 location
Post Approval Study for Treatment of Drug-resistant Adult Primary FSGS Using the LIPOSORBER LA-15 System

associated with primary focal segmental glomerulosclerosis, when the standard treatment options, including corticosteroid and/or calcineurin inhibitors treatments, have been unsuccessful or not well

calcineurin inhibitors
plasma cholesterol
remission
kidney transplant
nephrotic syndrome
  • 1 views
  • 05 May, 2021
  • 10 locations
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

develop individualized treatment options for future patients with TNF driven Focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD).

ace inhibitor
steroid therapy
total protein
angiotensin converting enzyme
enzyme inhibitor
  • 12 views
  • 26 Jan, 2021
  • 4 locations
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy Focal Segmental Glomerulosclerosis and Treatment-Resistant Minimal Change Disease

This is a phase 2a study evaluating the safety and tolerability of multiple ascending doses of GFB-887 in patients with diabetic nephropathy (DN), focal segmental glomerulosclerosis (FSGS), and

genetic testing
mammogram
glomerulosclerosis
type 2 diabetes
minimal change disease
  • 69 views
  • 01 Jul, 2021
  • 50 locations
Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome

change disease or focal segmental glomerulosclerosis unresponsive to 8 weeks of high dose prednisone . patients either receive 2 doses of Rituximab 375 mg/m2 iv at time 0 and 14 days with

prednisone 1 mg
nephrotic syndrome
total protein
prednisone
rituximab
  • 52 views
  • 22 Jan, 2021
  • 1 location
Atrasentan in Patients With Proteinuric Glomerular Diseases

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.

atrasentan
renal function
total protein
ras inhibitor
type 2 diabetes
  • 0 views
  • 17 Jul, 2021
  • 18 locations